Big Pharma is on the prowl for biotech companies, but it’s acting stingy. Deal sizes are smaller, valuations are reasonable and buyers are walking away from megadeals when sellers push too hard on ...

There are hundreds of biotechnology companies today that have never commercialized a drug. For many years, the standard approach in the industry has been to advance the science, prove the asset, and ...

Earnings season marches on. Two more Magnificent Seven tech companies—Alphabet and Amazon—will report, following on the heels of disappointing results from Microsoft that helped send software stocks ...

Some of the best-selling drugs in the world are facing a loss of exclusivity in key jurisdictions in the upcoming years in what the sector calls "the patent cliff." The need for pharma to top up their ...

Pharmaceutical companies are accused of abusing the patent system to keep drug prices high. Patent manipulation can delay the availability of cheaper generic alternatives for life-saving medications.

A biotechnology company has developed "what could turn out to be one of the most important cancer drugs in a generation," ...